AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends

AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Consistent Dividend Stocks to Buy Now.

AbbVie Inc. (NYSE:ABBV) is an Illinois-based pharmaceutical company. It has delivered strong results in 2025, easily beating the broader market. Much of this momentum comes from solid growth in sales and adjusted earnings, driven largely by its autoimmune treatments Rinvoq and Skyrizi. The stock has surged by nearly 22% since the start of 2025.

The strong performance of these two drugs has eased concerns about AbbVie Inc. (NYSE:ABBV)’s reliance on Humira, which lost US exclusivity in 2023. The company has managed that transition remarkably well and has shifted away from depending on Humira as its main growth engine.

In addition, AbbVie Inc. (NYSE:ABBV) is popular among income investors because of its dividend growth streak spanning 53 years. Currently, the company offers a quarterly dividend of $1.64 per share and has a dividend yield of 3%, as recorded on September 12.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Dividend Stocks to Buy for Retirement and 10 Best Strong Buy Dividend Stocks to Invest in Now.

Disclosure: None.